

Potent Therapeutic Efficacy of a Novel HPV16E7-HBcAg-Hsp65 Fusion Protein Vaccine

Chao Zhang[†], Chenliang Zhou[†], Xiaoliang Wang, Xinxing Ma, Meijun Diao, Haitao Liu, Dan Xu, Jian Wei, Yuanxiang Jiang, Menghua Zhang, Lingyun Zhou, Jiang Fan, Ge Liu*

Shanghai Zerun Biotechnology Co., Ltd., Shanghai, China.

ARTICLE INFO

Research Article

VacRes, 2021

Vol. 8, No.1, 60- 66

Received: November 24, 2021

Accepted: December 11, 2021

Pasteur Institute of Iran

*Corresponding Author:

Shanghai Zerun;
Biotechnology Co., Ltd.,
Shanghai, China.

Email: liuge@walvax.com

Tel/Fax: +86 21 8016 5098

[†]These authors contributed equally to this work.

KEYWORDS:

Human papillomaviruses, Therapeutic vaccine, Cervical cancer, T-cell response, Combination therapy

ABSTRACT

Introduction: Cervical cancer is the fourth leading cause of cancer death in women worldwide. Nearly all cervical cancers are resulted from high-risk Human Papillomavirus (HPV) infection. Currently, there is no available HPV-specific therapy. Cancer therapeutic vaccines have shown anti-tumor efficacy in preclinical animal models as well as clinical patients. **Methods:** Here, we used a previously-reported therapeutic vaccine candidate (VR₁₁₁) based on HPV16E7-HBcAg-Hsp65 fusion protein (with aluminum hydroxide adjuvant) and injected mice with 2 doses of VR₁₁₁ at a two-week interval 2 days after TC-1 tumor cell implantation. Tumor growth and animal survival rates were monitored and the vaccine-associated immune responses were evaluated by cytotoxic T lymphocytes assay, T-cell proliferation assay and CD4⁺/CD8⁺ T-cell depletion. **Results:** In TC-1 tumor murine model, VR₁₁₁ vaccine showed potent dose dependent therapeutic efficacy against tumor growth and improved survival rates in the medium (10 µg) and high doses (30 µg). The three fusion components of VR₁₁₁ were all necessary to induce the best anti-tumor activity, CTL response and T cell proliferation. The tumor growth inhibition and a higher mouse survival rate were among the beneficial effects of cisplatin-based combination treatment. Moreover, the anti-tumor potency of VR₁₁₁ vaccine was proved to be significantly associated with E7 specific CD8⁺ T cell immune response and the adoptive lymphocyte transfer therapy also showed tumor growth inhibition. **Conclusion:** The results confirmed VR₁₁₁ as a potent therapeutic HPV vaccine candidate with superior anti-tumor efficacy in a murine model of HPV-induced cancer which its potentials could be considered for combination therapies against cervical cancer.

Citation:

INTRODUCTION

High-risk human papillomavirus (HPV) infection has been firmly proved to be responsible for nearly all invasive cervical cancer, cervical pre-cancerous lesions and several other anogenital malignancies [1, 2]. According to the GLOBOCAN 2020 report, cervical cancer has dropped to the fourth most common cancer and the fourth most common cause of death from cancer in women due to the increasing coverage of prophylactic vaccination against HPV [3]. However, there is still no HPV-specific therapy and most used therapies involve removal or physical destruction of the lesions [4]. Recently, the WHO proposed to eliminate cervical cancer, and the third target is to reduce mortality from cervical cancer which needs more efficient therapies as well as preventing the relapses. The great successes of cancer immunotherapies using anti-PD1/PDL1 and CAR-T-cells, suggest the possibility of using therapeutic HPV vaccine as another promising option to fight against cervical cancer and a good candidate for combination therapy [5-10].

In China, high-risk type 16 (HPV16) was found to be positive in more than 60% of cervical intraepithelial neoplasia 2 or 3 (CIN2/3) and squamous cell carcinoma (SCC) samples [11, 12]. The genome integration and the interaction of non-structural proteins E6-p53, E7-pRb are thought to play important roles in the HPV-associated cervical carcinogenesis by disrupting the regulation of the cell cycle [13, 14]. Meanwhile, E7 protein is highly conserved genetically in pre-cancer/cancer patients, which makes it the optimum tumor specific antigen for a therapeutic vaccine design [15]. The relatively slow progression from CIN stages to advanced cancer also provides adequate time for the therapeutic intervention [14]. Multiple approaches have so far been taken to develop therapeutic HPV vaccines. Some of them targeted HPV16 E7 and/or E6 which have shown therapeutic benefits in CIN2/3 or cervical cancer [16-19].

In this study, we evaluated a previously-reported therapeutic vaccine candidate (VR₁₁₁), based on HPV16E7-HBcAg-Hsp65 fusion protein, formulated it with aluminum hydroxide adjuvant. The antigen HPV16 E7 nonstructural

protein and *Mycobacterium bovis* Bacille Calmette-Guérin (BCG) heat shock protein (Hsp65) were genetically fused to the N and C termini of the core antigen from hepatitis B virus (HBcAg), respectively. The self-assembly HBcAg is a flexible carrier to form virus-like particles (VLP) and Hsp65 was used to enhance antigen presentation as well as antigen specific cytotoxic T-lymphocyte responses [20-23]. In the previous study, VR₁₁₁ was shown to induce significant dose-dependent cellular (E7-specific) and humoral immune responses [24]. Thus, we hypothesized that VR₁₁₁ therapeutic vaccine could have a potent anti-tumor efficacy against the HPV16-induced cancer. The anti-tumor activity of VR₁₁₁ was evaluated in tumor-harboring mice and the results showed VR₁₁₁ could significantly inhibit the tumor growth alone or combined with cisplatin (an effective anticancer agent) [25, 26]. Moreover, the CD8⁺ T-cells played a major role in VR₁₁₁-induced immune responses against TC-1 tumor cells and the adoptive lymphocyte transfer therapy also showed anti-tumor effects.

MATERIALS AND METHODS

Ethical Statement

Ethical approval for treatment of the mice was granted by the Institutional Animal Care and Use Committee (IACUC) of National Center for Safety Evaluation of Drugs (NCSED) and National Institute for the Control of Pharmaceutical and Biological Products (NCPBP). The animal use was in line with the 3R (Reduction, Replacement, Refinement) principle and followed the Guide for the Care and Use of Laboratory Animals.

Mice and Cell Lines

Six to eight weeks old female C57BL/6 mice were purchased from Laboratory Animal Center of the Academy of Military Medical Sciences, Beijing, China. Animals were cared for under the standard protocols of the institutional committee. All animals were maintained under specific-pathogen-free conditions. TC-1 cells were provided by Shanghai Zerun Anke Biopharmaceutical company and were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin and streptomycin (100U/ml each) and L-glutamine (2mM) at 37°C with 5% CO₂. This cell line was derived from mouse lung epithelial cells and co-transformed by HPV16 E6/E7 and activated c-Ha-Ras [27].

Tumor Implantation and Treatment

TC-1 cells in log phase were implanted with 2×10⁵ cells/mouse subcutaneously (s.c.) in the right flank of each mouse on Day 0. Diameters of each tumor were measured every 3 or 4 days using digital caliper. Tumor volume was calculated using formula $V=1/2*a*b*b$, whereby “V” is volume, “a” is longer diameter and “b” is shorter diameter. In all experiments, mice were sacrificed when became moribund. Two days after tumor implantation, appropriate groups (n=10) were intramuscularly (i.m.) injected with VR₁₁₁, negative (normal saline) control or constituent controls twice with a 2-week interval. All antigens were expressed in *Escherichia coli* (SE1 strain) expression system and manufactured at Shanghai Zerun Biotechnology Co., Ltd [24]. Briefly, the codon optimized VR₁₁₁ fusion protein (823a.a.) gene sequence was constructed in pStabyl.2 vector and the expression was induced by IPTG (isopropyl-β-d-thiogalactoside). The recombinant bacteria were cultured in a 30 L fermentor. Recombinant protein was purified by cation and anion exchange chromatography and washed by

TritonX-100. The final endotoxin content was controlled to below 20 EU/mg. The purified antigen bulk (720 μg/ml) was then gently mixed with aluminum hydroxide diluent (2700 μg/ml) in a 2:1 volume ratio at 2 to 8°C for 15–20 h to prepare the final bulk. Each dose of VR₁₁₁ bulk was 0.5ml that contained 240 μg of fusion protein and 450 μg of aluminum hydroxide adjuvant in 50mM phosphate buffer (pH = 7.5). The constituent protein controls were also formulated with aluminum hydroxide adjuvant with the same concentrations. In the cisplatin combination treatment, 5 mg/kg cisplatin (Qilu Pharmaceutical, China) was intraperitoneally (i.p.) injected alone or combined with 10 μg i.m. immunized VR₁₁₁ vaccine. To visibly verify the anti-tumor growth, tumor tissues were dissected 17 days after tumor implantation followed by two times of injections.

Cytotoxic T lymphocytes (CTL) Assay

C57BL/6 mice harboring TC-1 tumor were treated as before and sacrificed two weeks after the second immunization. Splenocytes were collected and lymphocytes were isolated by using mouse lymphocytes separation medium (Hao Yang Bio, Tianjin, China). The lymphocytes were stimulated with 100 μg/ml E7₄₉₋₅₇ peptide (GL Biochem, Cat. 51582) in RPMI 1640 medium with 10% FBS for 3 days. Target TC-1 cells were labeled with ⁵¹Cr (PerkinElmerTM) by mixing 5×10⁴ cells/well with 3.7 MBq Na₂⁵¹CrO₄ in a 24-well plate and incubate at 37°C overnight. The effector T cells were diluted and added to incubate together with labeled target TC-1 cells at ratios (effector:target) of 30:1, 10:1, 3:1 for 6-8 hours at 37°C. The radioactivity was measured in 100 μl of cell culture supernatant. The percentage of lysis was calculated as previously described [28].

T-Cell Proliferation Assay

The lymphocytes were isolated as before and stimulated as triplicates with 100 μg/ml E7₄₉₋₅₇ peptide, 10 μg/ml Con A (Sigma) or blank negative control for 3 days at 37°C. After that, 0.2 μCi tritiated thymidine (³H-TDR, PerkinElmerTM) was added and incubated for another 24 hours. The T cell proliferation was determined by measuring methy-³H thymidine uptake in a liquid scintillation counter (PerkinElmerTM) as previously described [29]. The proliferation index was calculated using formula, proliferation index = (experimental signal - background) / (negative control signal - background).

CD4⁺/CD8⁺ T-Cell Depletion

Mice were intraperitoneally injected with 150 μg of either anti-CD4 (H129.19, BD Biosciences) or anti-CD8a (53-6.7, BD Biosciences) or both once a day in the first 3 days and then every other day till the end. Ten days after antibody injection, the CD4⁺ and CD8⁺ T lymphocytes were verified in one mouse from each group using flow cytometry assay. T lymphocytes were isolated and stained with PE-anti-CD4 and FITC-anti-CD8 (BD Biosciences). The percentages of each cell subset were measured by the Flow Cytometer (FC500MCL, Beckman). One day post depletion, mice were implanted with TC-1 cells and immunized with VR₁₁₁ as previously described. Tumor volumes and animal survival were recorded.

Adoptive Cell Transfer Assay

Donor mice were intramuscularly immunized twice at a 2-week interval. One week after the second immunization, the lymphocytes were isolated as before and 4×10⁶ cells were injected to the recipient mice through tail intravenous.

Recipient mice were implanted TC-1 tumor cells 1 day before. The tumor volumes were followed about 40 days and calculated as previously.

Statistical Analysis

All statistical parameters and significance between groups were calculated using GraphPad Prism 6.0 software (San Diego, CA). Statistical significance was determined by ordinary two-way ANOVA or student *t*-test ($p < 0.05$ was considered statistically significant).

RESULTS

Dose-Dependent Anti-Tumor Efficacy of VR₁₁₁

In our previous report, VR₁₁₁ induced dose dependent E7 epitope specific IFN- γ T-cell responses in mice [24]. Thus, we




Fig. 1. Dose-dependent therapeutic efficacy of VR₁₁₁ vaccine candidate against TC-1 tumor cells in mice. (A) Treatment schedule. C57BL/6 mice were implanted with 2×10^5 cells/mouse on day 0. VR₁₁₁ was intramuscularly injected twice at days 2 and 16. Tumor volume was measured every 3 or 4 days. (B) Tumor volumes of mice (n=10) injected with different doses of VR₁₁₁. The data represent means with standard deviation (SD). (C) The Kaplan-Meier plot depicts overall survival. (D) Tumor tissues dissected at day 17 after tumor implantation. NC, negative control.

Fusion with HBcAg and HSP65 Enhances Therapeutic Efficacy of VR₁₁₁

VR₁₁₁ vaccine candidate contains a fusion protein HPV16E7-HBcAg-Hsp65 expressed in *E. coli*. HPV16 E7 and HSP65 proteins were genetically linked to the N and C termini of HBcAg, respectively. Theoretically, the self-assembly of HBcAg could form small particles to enhance the antigenicity and HSP65 could also enhance the antigen presentation. In previous study, the addition of both HBcAg and HSP65 enhanced the E7 specific cellular and humor immune responses [24]. To verify the benefit of fusion protein design in an anti-tumor response context, we compared the efficacy of all the constituents of VR₁₁₁ in TC-1 model as before, either genetically fused or simply mixed. As shown in Fig. 2B, VR₁₁₁ showed the best therapeutic efficacy than any other constituent controls. Interestingly, E7 genetically fused with HSP65 also showed significant tumor growth inhibition (Fig. 2A, B). When we detected the antigen induced CTL lysis to TC-1 target cells or the proliferation capability *in vitro*, the E7 specific T-cell responses of each group was significantly associated with the tumor growth slowdown (Fig. 2C, D). These data suggest that

assumed that VR₁₁₁ was likely to have potent anti-tumor efficacy *in vivo*. We selected the 3 doses and detected the therapeutic efficacy in TC-1 tumor mice model. As showing in Fig. 1A, implanted TC-1 tumor mice were treated with three different doses of VR₁₁₁. The tumor growth of each mouse was monitored up to 46 days. The tumor volumes increased very rapidly when left untreated. However, two immunizations with VR₁₁₁ could significantly inhibit tumor growth in a dose dependent manner (Fig. 1B, D). Meanwhile, the treatment with the higher doses of the vaccine resulted in higher prolonged survival rates compared to the low dose or untreated mice. Importantly, both the 10 µg and 30 µg of the vaccine induced tumor regression in 70% of the treated mice (Fig. 1C, D). These results indicated that VR₁₁₁ vaccine candidate had significant anti-tumor activity in tumor-harboring C57BL/6 mice.

when genetically fused with HBcAg and HSP65, HPV16 E7 could induce significant improvement in T-cell responses and anti-tumor therapeutic efficacy.

Combination of VR₁₁₁ and Cisplatin Significantly Enhances Treatment Efficacy

Cisplatin is one of the most used regimens in locally advanced cervical cancer and has shown benefits in some combination therapies [4]. We thus hypothesized that combination of VR₁₁₁ and cisplatin could improve the efficacy of anti-tumor immunotherapy. To verify this hypothesis, we evaluated the treatment effects of cisplatin and VR₁₁₁, either alone or in combination, on tumor growth and survival of TC-1 tumor-harboring mice. While either VR₁₁₁ or cisplatin treatment alone resulted in slight inhibition of tumor growth, the combination treatment showed significant anti-tumor activity as well as a better survival rate (Fig. 3). These results indicate that combination of VR₁₁₁ with cisplatin treatment could be considered as a therapeutic strategy.




Fig. 2. Fusion of HBcAg and HSP65 enhances the therapeutic efficacy of VR₁₁₁ vaccine candidate. **(A)** Treatment schedule. TC-1 tumor mice were treated with 10 μ g of VR₁₁₁ or its constituents 2 days after tumor implantation. **(B)** Tumor volumes (means \pm SD) of mice (n=10) treated with VR₁₁₁ or its constituent controls. **(C)** Specific lysis percentages of CTL induced by different VR₁₁₁ treatments under 3 different ratios of effector to target cells. Effector cells, antigen specific T cells. Target cells, TC-1 cells. **(D)** Proliferation index of E7 epitope specific T cells in vitro. The error bar indicates the mean with SD (n=4).




Fig. 3. Combination therapy of cisplatin and VR₁₁₁ vaccine candidate enhances effect of anti-tumor treatment. **(A)** The TC-1 tumor-harboring C57BL/6 mice (n=10) were treated with VR₁₁₁ (10 μ g) alone or combined with cisplatin chemotherapy (5 mg/kg). Tumor volumes were recorded every 3-4 days. The error bar indicates the mean with SD. **(B)** The Kaplan-Meier plot depicts overall survival of the mice in each treatment group.

The Anti-Tumor Potency of VR₁₁₁ Was Mediated by CD8⁺ T-Cells

To further investigate the mechanism of immunotherapy induced by VR₁₁₁ vaccination, we depleted CD4⁺ and/or CD8⁺ T cells by i.p. injection of anti-CD4 and anti-CD8a antibodies. Next, the implanted TC-1 tumor C57BL/6 mice were injected twice with VR₁₁₁ as before (Fig. 4A). The depletion efficiency was verified using flow cytometry. Nearly, all CD4⁺ and/or CD8⁺ T cells were depleted in vivo (Fig. 4B). In tumor treatments, only the mice with CD8⁺ T cells showed significant better anti-tumor responses and survival rates (Fig. 4C, 4D). These data demonstrate that the CD8⁺ T cells play the major role in VR₁₁₁-induced cellular immune responses against TC-1 tumor.

VR₁₁₁ Mediated Adoptive Lymphocytes Transfer Anti-Tumor Therapy

Since VR₁₁₁ inhibited tumor growth by inducing specific T-cell immune responses, adoptive T cell transfer could also be performed to confirm its anti-tumor effect. Therefore, we isolated the lymphocytes from mice immunized with VR₁₁₁ or E7 alone and then transferred the lymphocytes into TC-1 tumor implanted mice through tail intravenous injection (Fig. 5A). As shown in Fig. 2, VR₁₁₁ vaccine could significantly induce a higher T-cell response than E7 treatment. Likewise, VR₁₁₁ showed better tumor growth inhibition compared to E7 alone ($p < 0.05$) and the negative treatment (saline) control ($p < 0.001$). This indicated that the efficacy of adoptive cell transfer therapy

was highly associated with the antigen-specific cellular immune responses (Fig. 5B).




Fig. 4. CD8⁺ T-cells played a major role in VR₁₁₁ induced immune responses against TC-1 tumor cells. (A) Treatment schedule. Mice were intraperitoneally injected with 150 µg of either anti-CD4 antibody or anti-CD8a antibody or both once a day in the first 3 days and then every other day till the end. One day post depletion, mice were implanted with TC-1 cells and immunized with VR₁₁₁ as previously described. (B) CD4⁺ and/or CD8⁺ T cells subsets depletion verification by flow cytometry. (C) Tumor volumes of mice (n=8~10) depleted with either CD4⁺ or CD8⁺ T cells or both and then followed with previous described tumor implantation and VR₁₁₁ treatment. The data represent means with SD. (D) The Kaplan-Meier plot depicts the overall survival of the mice.




Fig. 5. Adoptive lymphocytes transfer anti-tumor therapy of VR₁₁₁. (A) Treatment schedule. Lymphocytes from VR₁₁₁ immunized the donor mice (n=4) were isolated and injected into the recipient TC-1 implanted mice (n=10). (B) Tumor volumes of the recipient mice measured were every 3-4 days. The data represent means with SD.

DISCUSSION

Although the implementation of prophylactic HPV vaccines may gradually decrease the incidence of cervical cancer or high-grade squamous intraepithelial lesion (HSIL) resulted from high-risk HPV (hrHPV) infections in the future, cervical cancer is still one of the leading causes of cancer deaths for women in more than 30 countries [3]. HPV16 remains among the most prevalent hrHPV genotypes of cervical lesions [30]. The progression of cervical cancerogenesis results from hrHPV gene integration, following by sustained expression of nonstructural proteins E6 and E7, which lead to uncontrolled cellular proliferation by mediating the degradation of p53 and pRB [2]. The highly significant expression of E7 in clinically- malignant lesions of the uterine cervix, makes E7 antigen an ideal tumor-associated antigen for HPV therapeutic vaccine development [31]. HPV16 E7-based therapeutic vaccines, either alone or combined with E6 or L2 protein, have been evaluated in clinical trials. A covalently linked HPV16 E7 to Hsp65 (a therapeutic vaccine candidate; HspE7) was previously shown to prime a potent E7-specific CD8⁺ T cell response and showed moderate therapeutic efficacy in treatment of CIN3[32, 23]. Novel adjuvants including imiquimod, GPI-0100 or CpG have been evaluated in E7-based recombinant protein vaccines to enhance the antigen specific T cell responses[33-35]. Moreover, the self-assembly and high degree of immunogenicity of hepatitis B virus core protein has already been used as an antigen carrier and shown protective efficacy in animal models of malaria, influenza, Lyme disease as well as TC-1 tumor mice model when carrying HPV 16 E7 epitopes[20, 36]. Therefore, we assayed a previously-constructed therapeutic vaccine candidate (VR₁₁₁), formulated with HPV16E7-HBcAg-Hsp65 fusion protein and aluminum hydroxide adjuvant. In our previous investigation, VR₁₁₁ was able to form macromolecules with a z-average radius of about 46.04 nm and induce significant E7-specific cellular and humoral immune responses in mice [24].

In this study, the anti-tumor activity of VR₁₁₁ vaccine was evaluated in TC-1 tumor-bearing mice. The results indicated potent therapeutic efficacy of VR₁₁₁ vaccine candidate which was associated with E7 specific CD8⁺ T cell immune response. Since cisplatin alone or in combination with radiation is still considered as the standard effective treatment for patients with advanced or recurrent cervical cancer in many, other combinations with vaccines or monoclonal antibodies are also attractive combination therapies[37]. Our results also indicated that a combination treatment with VR₁₁₁ and cisplatin could enhance the overall antitumor effects. Moreover, an adoptive cell transfer therapy showed significant tumor growth inhibition in our animal model.

Nevertheless, there are some limitations for this study. The anti-tumor effects might be limited to the murine model, based on the transformed TC-1 cell line and not due to a natural hrHPV persistent infection. In the present design of VR₁₁₁ vaccine candidate, E7 was chosen to be the only target tumor-associated antigen. However, since E6 and E7 are the induction factors of the cervical cancer progression, therapeutic vaccines targeting both E6 and E7 might be more efficient [38]. Furthermore, more adjuvants other than aluminum hydroxide could be screened; as Poly (I : C) or CpG oligodeoxynucleotide adjuvants formulated with HPV synthetic peptides are shown to enhance the specific CD8⁺ T cell responses and tumor growth inhibition [39, 40].

Similar to other therapeutic vaccine-based combination treatments, such as PD-1 immune checkpoint blockade, VR₁₁₁ vaccine candidate, combined with the anticancer drug "cisplatin" demonstrated better anti-tumor response with synergistic effects [41]. Our CD4⁺ and/or CD8⁺ T-cells depletion experiment indicated that CD8⁺ T cells plays a major role in VR₁₁₁-induced tumor growth inhibition. Previous results from an adoptive lymphocyte transfer therapy experiment has also confirmed the T-cell mediated cancer immunotherapy and suggested potential optimized adoptive cell transfer therapy using in vitro amplified antigen specific T cells [42].

Altogether, VR₁₁₁ as a therapeutic vaccine candidate showed efficient anti-tumor effects and increased survival rates in tumor-harboring C57BL/6 mice by improving treatment dose and cellular immune responses. These results suggest that VR₁₁₁ is a promising candidate for cervical cancer immunotherapy.

ACKNOWLEDGMENT

This work was supported by National Science and Technology of China (no. 2009ZX09103-611), the National Great Science and Technology project (no. 2013ZX09102-059) and the Shanghai Science and Technology Committee (no. 0902H111900). We also appreciated the support of Donghou Li and his crew from the Experimental Laboratory of Pathology, Institute of Radiation Medicine, Academy of Military Medical Sciences, China.

CONFLICTS OF INTEREST

All the authors are current employees of Shanghai Zerun Biotechnology Co., Ltd.

REFERENCES

- Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *J Pathol.* 1999;189(1):12-9. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.
- Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives. *J Oncol.* 2019;2019:3257939. doi:10.1155/2019/3257939.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209-49. doi:10.3322/caac.21660.
- Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of oncology : official journal of the European Society for Medical Oncology.* 2017;28(suppl_4):iv72-iv83. doi:10.1093/annonc/mdx220.
- Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth, II. Therapeutic vaccines for high-risk HPV-associated diseases. *Papillomavirus research.* 2018;5:46-58. doi:10.1016/j.pvr.2017.12.006.
- Banchereau J, Palucka K. Cancer vaccines on the move. *Nature Reviews Clinical Oncology.* 2017;15:9. doi:10.1038/nrclinonc.2017.149.
- Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. *Nature Reviews Immunology.* 2017;18:168. doi:10.1038/nri.2017.131.
- Grenier JM, Yeung ST, Khanna KM. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. *Frontiers in immunology.* 2018;9:610. doi:10.3389/fimmu.2018.00610.
- Rice AE, Latchman YE, Balint JP, Lee JH, Gabitzsch ES, Jones FR. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. *Cancer gene therapy.* 2015;22(9):454-62. doi:10.1038/cgt.2015.40.

10. Mkrtychyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J et al. Anti-PD-1 antibody significantly increases therapeutic efficacy of *Listeria monocytogenes* (Lm)-LLO immunotherapy. *Journal for immunotherapy of cancer*. 2013;1:15. doi:10.1186/2051-1426-1-15.
11. Chen W, Molijn A, Enqi W, Zhang X, Jenkins D, Yu X et al. The variable clinicopathological categories and role of human papillomavirus in cervical adenocarcinoma: A hospital based nation-wide multi-center retrospective study across China. *International journal of cancer*. 2016;139(12):2687-97. doi:10.1002/ijc.30401.
12. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W et al. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. *Cancer causes & control : CCC*. 2009;20(9):1705-13. doi:10.1007/s10552-009-9422-z.
13. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. *Nature reviews Cancer*. 2010;10(8):550-60. doi:10.1038/nrc2886.
14. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. *Nature reviews Cancer*. 2007;7(1):11-22. doi:10.1038/nrc2050.
15. Mirabello L, Yeager M, Yu K, Clifford GM, Xiao Y, Zhu B et al. HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. *Cell*. 2017;170(6):1164-74 e6. doi:10.1016/j.cell.2017.08.001.
16. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. *Lancet (London, England)*. 2015;386(10008):2078-88. doi:10.1016/s0140-6736(15)00239-1.
17. Garcia F, Petry KU, Muderspach L, Gold MA, Braly P, Crum CP et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. *Obstet Gynecol*. 2004;103(2):317-26. doi:10.1097/01.AOG.0000110246.93627.17.
18. Basu P, Mehta A, Jain M, Gupta S, Nagarkar RV, John S et al. A Randomized Phase 2 Study of ADXS11-001 *Listeria monocytogenes*-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer. *International journal of gynecological cancer : official journal of the International Gynecological Cancer Society*. 2018;28(4):764-72. doi:10.1097/igc.0000000000001235.
19. Greenfield WW, Stratton SL, Myrick RS, Vaughn R, Donnalley LM, Coleman HN et al. A phase I dose-escalation clinical trial of a peptide-based human papillomavirus therapeutic vaccine with Candida skin test reagent as a novel vaccine adjuvant for treating women with biopsy-proven cervical intraepithelial neoplasia 2/3. *Oncoimmunology*. 2015;4(10):e1031439. doi:10.1080/2162402X.2015.1031439.
20. Whitacre DC, Lee BO, Milich DR. Use of hepadnavirus core proteins as vaccine platforms. *Expert review of vaccines*. 2009;8(11):1565-73. doi:10.1586/erv.09.121.
21. Schumacher J, Bacic T, Staritzbichler R, Daneschdar M, Klamp T, Arnold P et al. Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. *Journal of nanobiotechnology*. 2018;16(1):39. doi:10.1186/s12951-018-0363-0.
22. Bolhassani A, Rafati S. Heat-shock proteins as powerful weapons in vaccine development. *Expert review of vaccines*. 2008;7(8):1185-99. doi:10.1586/14760584.7.8.1185.
23. Einstein MH, Kadish AS, Burk RD, Kim MY, Wadler S, Streicher H et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. *Gynecologic oncology*. 2007;106(3):453-60. doi:10.1016/j.ygyno.2007.04.038.
24. Zhou CM, Zhang GX, Ma XX. Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein. *Journal of virological methods*. 2014;197:1-6. doi:10.1016/j.jviromet.2013.10.033.
25. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. *Drug design, development and therapy*. 2016;10:1885-95. doi:10.2147/dddt.s106412.
26. Lorusso D, Petrelli F, Coinu A, Raspagliesi F, Barni S. A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. *Gynecologic oncology*. 2014;133(1):117-23. doi:10.1016/j.ygyno.2014.01.042.
27. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. *Cancer Res*. 1996;56(1):21-6.
28. Marr RA, Addison CL, Snider D, Muller WJ, Gaudie J, Graham FL. Tumour immunotherapy using an adenoviral vector expressing a membrane-bound mutant of murine TNF alpha. *Gene therapy*. 1997;4(11):1181-8. doi:10.1038/sj.gt.3300528.
29. Diaz-Benitez CE, Navarro-Fuentes KR, Flores-Sosa JA, Juarez-Diaz J, Uribe-Salas FJ, Roman-Basauré E et al. CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. *Journal of clinical immunology*. 2009;29(4):532-44. doi:10.1007/s10875-009-9279-7.
30. Xia C, Li S, Long T, Chen Z, Chan PKS, Boon SS. Current Updates on Cancer-Causing Types of Human Papillomaviruses (HPVs) in East, Southeast, and South Asia. *Cancers*. 2021;13(11):2691. doi:10.3390/cancers13112691.
31. Ramirez N, Guerra F, Camporeale G, Quintana S, Diaz LB, Cuneo N et al. Expressions of E2 and E7-HPV16 proteins in pre-malignant and malignant lesions of the uterine cervix. *Biotech Histochem*. 2015;90(8):573-80. doi:10.3109/10520295.2015.1047794.
32. Liu H, Wu BH, Rowse GJ, Emtage PC. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. *Clinical and vaccine immunology : CVI*. 2007;14(8):1013-23. doi:10.1128/CVI.00029-07.
33. Esquerre M, Bouillette-Marussig M, Goubier A, Momot M, Gonindard C, Keller H et al. GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression. *PloS one*. 2017;12(3):e0174038. doi:10.1371/journal.pone.0174038.
34. Karanam B, Gambhira R, Peng S, Jagu S, Kim DJ, Ketner GW et al. Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. *Vaccine*. 2009;27(7):1040-9. doi:10.1016/j.vaccine.2008.11.099.
35. Da Silva DM, Skeate JG, Chavez-Juan E, Luhen KP, Wu JM, Wu CM et al. Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease. *Vaccine*. 2019;37(22):2915-24. doi:10.1016/j.vaccine.2019.04.043.
36. Chu X, Li Y, Long Q, Xia Y, Yao Y, Sun W et al. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model. *Int J Nanomedicine*. 2016;11:2417-29. doi:10.2147/IJN.S102467.
37. Kumar L, Harish P, Malik PS, Khurana S. Chemotherapy and targeted therapy in the management of cervical cancer. *Curr Probl Cancer*. 2018;42(2):120-8. doi:10.1016/j.cuprocancer.2018.01.016.
38. Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. *Front Microbiol*. 2019;10:3116. doi:10.3389/fmicb.2019.03116.
39. Rahimian S, Franssen MF, Kleinovink JW, Christensen JR, Amidi M, Hennink WE et al. Polymeric nanoparticles for co-delivery of synthetic long peptide antigen and poly IC as therapeutic cancer vaccine formulation. *J Control Release*. 2015;203:16-22. doi:10.1016/j.jconrel.2015.02.006.
40. Zhao Y, Wang H, Yang Y, Jia W, Su T, Che Y et al. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice. *Int J Nanomedicine*. 2020;15:9571-86. doi:10.2147/IJN.S275670.
41. Peng S, Tan M, Li YD, Cheng MA, Farmer E, Ferrall L et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. *Cancer immunology, immunotherapy : CII*. 2021;70(4):1049-62. doi:10.1007/s00262-020-02754-x.
42. Labarriere N, Khammari A, Lang F, Dreno B. Is antigen specificity the key to efficient adoptive T-cell therapy. *Immunotherapy*. 2011;3(4):495-505. doi:10.2217/imt.11.16.